Background of the Legal Dispute
On July 3, 2026, MMJ International Holdings, Inc. (MMJIH) issued a public statement responding to the U.S. Department of Justice’s (DOJ) latest filing before the U.S. Court of Appeals for the District of Columbia Circuit. The filing concerns Attorney General Order No. 6754‑2026, which the DOJ argues limits the applicability of the Controlled Substances Act (CSA) to entities that have not yet secured Food and Drug Administration (FDA) approval for a cannabinoid‑based product. MMJIH, together with its subsidiaries MMJ BioPharma Cultivation, Inc. and MMJ BioPharma Labs, Inc., contends that the DOJ’s position undermines the very purpose of the CSA: to protect public health, scientific integrity, and public safety.
MMJIH has pursued a federally compliant research agenda for more than eight years, developing investigational medicines for Huntington’s disease and multiple sclerosis through the FDA’s Investigational New Drug (IND) pathway. The company holds two active IND applications, an Orphan Drug Designation, a DEA Schedule I analytical laboratory registration, and has sought a DEA bulk manufacturing registration since 2018 to cultivate pharmaceutical‑grade cannabis for authorized clinical trials.
The Regulatory Paradox: Compliance as a Competitive Disadvantage
MMJIH’s legal brief highlights what it describes as a “regulatory paradox.” While companies that follow the FDA‑approved and DEA requirements—such as MMJIH—must navigate lengthy FDA reviews, DEA registrations, and substantial financial outlays, the DOJ is simultaneously defending an order that extends significant federal benefits to state‑licensed marijuana businesses that have largely bypassed the FDA approval process. According to the filing, this creates a marketplace where adherence to federal standards is treated as a liability rather than a credential of legitimacy.
Duane Boise, CEO of MMJ International Holdings, emphasized the contradiction:
“For eight years, we have done exactly what the government demanded. We followed the FDA pathway, complied with the DEA, and invested over $15 million in drug development for clinical research. Now, the DOJ tells the Court our injuries don’t matter because we haven’t completed the very process they forced us to navigate.”
The company argues that if entities ignoring the federal pharmaceutical pathway receive the same or greater governmental incentives, compliance ceases to be rewarded and instead becomes a competitive handicap. This, MMJIH asserts, risks encouraging a “wild west” approach to medicine, contrary to Congress’s intent when enacting the CSA in 1970.
Impact on Public Safety Infrastructure
The DOJ’s filing also seeks to dismiss concerns raised by the National Drug and Alcohol Screening Association (NDASA), asserting that Congress did not enact the CSA to provide revenue for drug‑screening organizations. MMJIH counters that workplace drug testing serves a critical public‑safety function across transportation, aviation, healthcare, and other safety‑sensitive sectors. The organization cites data from the Substance Abuse and Mental Health Services Administration (SAMHSA) indicating that over 10 million workplace drug tests were conducted in the United States in 2025, helping to identify impairment that could jeopardize public safety.
Boise noted:
“The government’s brief treats workplace drug testing as though it exists simply to generate revenue. That completely misses the point. Drug testing protects the traveling public, hospital patients, and workers in safety‑sensitive occupations. Suggesting these interests fall outside the purpose of the Controlled Substances Act should concern every American.”
The D.C. Circuit’s Role in Shaping Federal Drug Policy
The consolidated appeals pending before the U.S. Court of Appeals for the District of Columbia Circuit will determine whether Attorney General Order No. 6754‑2026 was lawfully issued and whether the DOJ possesses the authority to create the regulatory framework it advocates. A ruling in favor of MMJIH could reinforce the principle that compliance with FDA and DEA requirements remains a protected interest under the CSA. Conversely, a decision supporting the DOJ’s stance might signal a shift toward de‑emphasizing federal oversight in favor of state‑driven cannabis markets.
Legal scholars note that the case touches on longstanding debates about the balance between federal preemption and state experimentation in drug policy. References to precedents such as Gonzales v. Raich, 545 U.S. 1 (2005), and United States v. Oakland Cannabis Buyers’ Cooperative, 532 U.S. 483 (2001), are likely to feature in the parties’ briefs as the court evaluates the scope of congressional authority under the CSA.
Conclusion
MMJ International Holdings frames the ongoing litigation as more than a dispute over marijuana; it characterizes the conflict as a fundamental test of federal regulatory integrity. By arguing that FDA‑backed clinical development and workplace safety standards fall outside the CSA’s protective scope, the government, according to MMJIH, risks incentivizing non‑compliance and undermining the safeguards Congress intended to uphold. As the D.C. Circuit prepares to weigh the arguments, the outcome may have lasting implications for how the United States balances innovation, public safety, and federal oversight in the evolving landscape of cannabinoid‑based medicine.
For the original press release, see the source: Here
